Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
April 29, 2026 expert reaction to RCT which looks at semaglutide and motivation in depression . A randomised controlled trial published in JAMA Psychiatry looks at semaglutide use ...
Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a ...
An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
Zacks Investment Research on MSN
Will AbbVie's neuroscience franchise aid top-line growth in Q1?
AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results